Non-public Advisor Group LLC lessened its place in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 1.4% in the course of the third quarter, in response to its most up-to-date submitting with the Securities and Change Fee (SEC). The fund owned 159,421 shares of the healthcare product maker’s inventory after promoting 2,295 shares in the course of the interval. Non-public Advisor Group LLC’s holdings in Abbott Laboratories have been price $18,238,000 on the finish of the newest reporting interval.
Different institutional traders and hedge funds additionally lately made modifications to their positions within the firm. Distinctive Wealth Methods LLC bought a brand new place in shares of Abbott Laboratories within the second quarter price about $28,000. Redmont Wealth Advisors LLC purchased a brand new place in Abbott Laboratories within the 1st quarter price roughly $30,000. Future Monetary Wealth Managment LLC bought a brand new place in Abbott Laboratories within the third quarter valued at roughly $31,000. Itau Unibanco Holding S.A. purchased a brand new stake in Abbott Laboratories in the course of the 2nd quarter valued at $32,000. Lastly, Ridgewood Investments LLC bought a brand new stake in shares of Abbott Laboratories in the course of the second quarter price $37,000. Institutional traders personal 75.18% of the corporate’s inventory.
Wall Road Analysts Forecast Progress
Numerous analysts lately issued stories on ABT shares. Piper Sandler elevated their value goal on Abbott Laboratories from $131.00 to $133.00 and gave the inventory an “obese” ranking in a report on Thursday, October seventeenth. Jefferies Monetary Group elevated their value goal on shares of Abbott Laboratories from $120.00 to $125.00 and gave the inventory a “maintain” ranking in a report on Thursday, October seventeenth. UBS Group upped their goal value on shares of Abbott Laboratories from $143.00 to $146.00 and gave the inventory a “purchase” ranking in a report on Thursday, October seventeenth. Edward Jones downgraded shares of Abbott Laboratories from a “purchase” ranking to a “maintain” ranking in a report on Tuesday, July thirtieth. Lastly, Morgan Stanley upped their value goal on shares of Abbott Laboratories from $107.00 to $117.00 and gave the inventory an “equal weight” ranking in a report on Thursday, October seventeenth. 4 analysis analysts have rated the inventory with a maintain ranking and twelve have given a purchase ranking to the corporate. In line with MarketBeat, the inventory presently has a mean ranking of “Reasonable Purchase” and a mean goal value of $129.67.
Test Out Our Newest Evaluation on ABT
Insider Shopping for and Promoting at Abbott Laboratories
In different information, CEO Robert B. Ford offered 141,679 shares of the inventory in a transaction dated Thursday, September twelfth. The shares have been offered at a mean value of $116.41, for a complete transaction of $16,492,852.39. Following the completion of the sale, the chief government officer now straight owns 220,059 shares within the firm, valued at roughly $25,617,068.19. This represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a doc filed with the SEC, which is accessible by this hyperlink. Company insiders personal 1.10% of the corporate’s inventory.
Abbott Laboratories Inventory Efficiency
Shares of NYSE ABT opened at $116.99 on Thursday. The inventory’s 50-day shifting common is $114.46 and its 200 day shifting common is $108.62. The inventory has a market cap of $203.52 billion, a price-to-earnings ratio of 36.45, a P/E/G ratio of two.74 and a beta of 0.72. Abbott Laboratories has a 1-year low of $91.64 and a 1-year excessive of $121.64. The corporate has a present ratio of 1.68, a fast ratio of 1.18 and a debt-to-equity ratio of 0.33.
Abbott Laboratories (NYSE:ABT – Get Free Report) final introduced its quarterly earnings outcomes on Wednesday, October sixteenth. The healthcare product maker reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.01. The enterprise had income of $10.64 billion for the quarter, in comparison with analysts’ expectations of $10.55 billion. Abbott Laboratories had a return on fairness of 20.18% and a internet margin of 13.65%. The enterprise’s quarterly income was up 4.9% on a year-over-year foundation. Throughout the identical interval within the earlier yr, the agency earned $1.14 EPS. On common, sell-side analysts anticipate that Abbott Laboratories will put up 4.66 EPS for the present fiscal yr.
Abbott Laboratories Dividend Announcement
The corporate additionally lately declared a quarterly dividend, which can be paid on Friday, November fifteenth. Shareholders of file on Tuesday, October fifteenth can be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized foundation and a yield of 1.88%. The ex-dividend date of this dividend is Tuesday, October fifteenth. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.
Abbott Laboratories Profile
Abbott Laboratories, along with its subsidiaries, discovers, develops, manufactures, and sells well being care merchandise worldwide. It operates in 4 segments: Established Pharmaceutical Merchandise, Diagnostic Merchandise, Dietary Merchandise, and Medical Units. The corporate gives generic prescribed drugs for the remedy of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive signs, gynecological dysfunction, hormone alternative remedy, dyslipidemia, hypertension, hypothyroidism, Ménière’s illness and vestibular vertigo, ache, fever, irritation, and migraine, in addition to gives anti-infective clarithromycin, influenza vaccine, and merchandise to control physiological rhythm of the colon.
Additional Studying
Obtain Information & Rankings for Abbott Laboratories Day by day – Enter your e-mail handle under to obtain a concise day by day abstract of the newest information and analysts’ rankings for Abbott Laboratories and associated firms with MarketBeat.com’s FREE day by day e-mail publication.
